News

Novo Nordisk falls as company slashes 2025 forecasts as US sales of Wegovy and Ozempic face headwinds from compounded drugs.
South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...
LTZ's research collaboration with Lilly advances development of its novel Myeloid Engager Platform, addressing diseases with ...
Novo Nordisk named Maziar Mike Doustdar as its new chief executive today, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug ...
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...
Novo Nordisk announced company veteran Maziar Mike Doustdar as its next CEO, as the firm struggles to regain its dominance in ...
Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...